ArticleBMC cancer2025
Niosomal mefloquine and cisplatin in breast cancer: comparative effects on apoptosis and angiogenesis via in vitro and in silico analysis.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundBreast cancer remains a leading cause of cancer-related death among females, with triple-negative breast cancer (TNBC) posing significant therapeutic challenges due to its aggressive behavior and lack of targeted treatments. Mefloquine (MEF), an antimalarial agent, exhibits anticancer activity by disrupting lysosomal function and enhancing ROS-mediated apoptosis. Cisplatin (CIS) induces apoptosis but is limited by drug resistance. This study investigates the combined effects of MEF, in both free and niosomal forms, and CIS on apoptosis and angiogenesis in breast cancer cells.
methodsThe cytotoxicity of MEF, CIS, and their combinations was assessed in MCF-7 and TNBC cell lines using MTT assays. Gene expression and ELISA analysis confirmed significant upregulation of pro-apoptotic markers Bax (p < 0.001) and CASP3 (p < 0.001), and downregulation of anti-apoptotic Bcl-2 (p < 0.001) and angiogenic factors VEGF and KDR. Molecular docking studies (Molegro Virtual Docker) evaluated binding affinities of MEF and CIS to BAX, Bcl-2, and VEGFR. NMEF was prepared and characterized for stability and encapsulation efficiency.
resultsNMEF demonstrated high encapsulation efficiency (87.21%) and was stable over six months. Combination treatments, particularly Cisplatin-niosomal Mefloquine (CIS-NMEF), showed synergistic cytotoxicity (CI < 1) and significantly lower IC50 values in both cell lines (TNBC: 2.30 µg/ml). Molecular docking revealed strong binding affinities for CIS-NMEF with BAX (-139.72), Bcl-2 (-136.09), and VEGFR (-139.19). Gene expression analysis confirmed upregulation of pro-apoptotic markers (Bax, CASP3) and downregulation of anti-apoptotic *Bcl-2* and angiogenic factors (VEGF, KDR). ROS production increased significantly in combination groups, indicating enhanced oxidative stress.
conclusionThe niosomal formulation of MEF synergistically enhances CIS efficacy by promoting apoptosis, and suppressing angiogenesis in TNBC. These findings highlight NMEF as a promising chemosensitizer to overcome cisplatin resistance. Future studies should focus on in vivo validation and clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.